2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more
2Seventy Bio Inc (TSVT) - Total Liabilities
Latest total liabilities as of March 2025: $266.04 Million USD
Based on the latest financial reports, 2Seventy Bio Inc (TSVT) has total liabilities worth $266.04 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
2Seventy Bio Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how 2Seventy Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
2Seventy Bio Inc Competitors by Total Liabilities
The table below lists competitors of 2Seventy Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
|
China | CN¥2.17 Billion |
|
Lintes Technology Co Ltd
TW:6715
|
Taiwan | NT$1.00 Billion |
|
Shenzhen Wongtee International Enterprise Co Ltd
SHE:000056
|
China | CN¥4.23 Billion |
|
CK Life Sciences Int'l. (Holdings) Inc
F:LSI
|
Germany | €7.63 Billion |
|
Beijing Changjiu Logistics Ltd
SHG:603569
|
China | CN¥2.80 Billion |
|
Movida Participações S.A
SA:MOVI3
|
Brazil | R$26.85 Billion |
|
Nanjing Panda Electronics Company Limited
F:NNJ
|
Germany | €1.72 Billion |
|
Penns Woods Bancorp Inc
NASDAQ:PWOD
|
USA | $2.04 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down 2Seventy Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 2Seventy Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 2Seventy Bio Inc (2019–2024)
The table below shows the annual total liabilities of 2Seventy Bio Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $268.70 Million | -13.36% |
| 2023-12-31 | $310.13 Million | -10.42% |
| 2022-12-31 | $346.20 Million | -13.42% |
| 2021-12-31 | $399.85 Million | +68.01% |
| 2020-12-31 | $237.99 Million | -12.26% |
| 2019-12-31 | $271.26 Million | -- |